Acute Myelogenous Leukemia (AML) News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Acute Myeloid Leukemia Pricing, Reimbursement, and Access 2017: Examine Payer Views on Recently Approved and ... - PR Newswire (press release)



Acute Myeloid Leukemia Pricing, Reimbursement, and Access 2017: Examine Payer Views on Recently Approved and ... 
PR Newswire (press release)
The level of concern surrounding the budget impact of acute myeloid leukemia (AML) has traditionally been low due to the relatively small size of the population in comparison to solid tumors, the high severity of the disease, and a lack of branded ...

and more » 


Dr. Wang on Results With Crenolanib Plus Chemotherapy in AML - OncLive



OncLive
 
Dr. Wang on Results With Crenolanib Plus Chemotherapy in AML 
OncLive
Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the results of the combination of crenolanib plus chemotherapy in a study of patients with acute myeloid ...

 


Medigene gets OK for first trial of T-cell receptor therapy ... - FierceBiotech



FierceBiotech
 
Medigene gets OK for first trial of T-cell receptor therapy ... 
FierceBiotech
Medigene has been given a green light by regulators in Germany to start human trials of MDG1011, the lead candidate to come out of its modified T-cell program. The Munich-based biotech says it will start a combined phase 1/2 safety and feasibility ...

and more » 


Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM ... - PR Newswire (press release)



PR Newswire (press release)
 
Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM ... 
PR Newswire (press release)
SAN DIEGO, Feb. 6, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that the first patient has completed the first cycle of dosing with PCM-075 in combination with low-dose cytarabine in ...

and more » 


FULL CIRCLE: Son gives caring father a life-saving gift - FOX 10 News Phoenix



FOX 10 News Phoenix
 
FULL CIRCLE: Son gives caring father a life-saving gift 
FOX 10 News Phoenix
Sabbah, now 88, was diagnosed with Acute Myelogenous Leukemia (AML) in March, following a routine blood exam. Rev. Sabbah's chance of survival was slim, and the only life saving treatment was induction chemotherapy, followed by a stem cell transplant ...

 


Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect? - Nasdaq



Nasdaq
 
Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect? 
Nasdaq
Noticeably, there was no report of significant sales from the company's drug, Vyxeos, last quarter, which was launched in August 2017 in the U.S. market for treatment of adults with acute myeloid leukemia (AML). However, the drug is expected to ...

and more » 


Rockin' to Beat: Leukemia Fundraiser honoring 'Lu' returns for second year - ThisWeek Community News



ThisWeek Community News
 
Rockin' to Beat: Leukemia Fundraiser honoring 'Lu' returns for second year 
ThisWeek Community News
When 17-year-old Lauryn Oliphant lost her 18-month battle with acute myelogenous leukemia in May 2016, her parents grieved both privately and with high school students and others from Pickerington and throughout central Ohio who were touched personally ...

 


H3 Biomedicine Preclinical Proof-of-Concept Data on First-in-Class Spliceosome-Modulator Therapy for Genomically ... - Business Wire (press release)



H3 Biomedicine Preclinical Proof-of-Concept Data on First-in-Class Spliceosome-Modulator Therapy for Genomically ... 
Business Wire (press release)
Mutations in genes encoding for certain of these RNA splicing factors that form the spliceosome are among the most common mutations found in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia ...

and more » 


Acute myeloid leukaemia (AML) and cytarabine pharmacogenomics - Open Access Government



Open Access Government
 
Acute myeloid leukaemia (AML) and cytarabine pharmacogenomics 
Open Access Government
Acute myeloid leukaemia (AML) is the cancer of the myeloid precursor stem cells characterised by the appearance of immature, abnormal myeloid cells in bone marrow and other organs. AML is a very heterogeneous disease with various subtypes classified ...

 


FDA Grants Priority Review to Ivosidenib for IDH1+ AML - OncLive



OncLive
 
FDA Grants Priority Review to Ivosidenib for IDH1+ AML 
OncLive
?After decades of little change, treatment of AML has begun to shift dramatically as result of new therapies, and IDH mutation inhibitors will play an important role in how we treat this terrible disease,? David Schenkein, MD, chief executive officer ...
FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an ... GlobeNewswire (press release)
FDA accepts Agios Pharma's marketing application for ivosidenib for AML Seeking Alpha
Agios Pharma (AGIO) Says FDA Accepted NDA and Granted Priority Review for Ivosidenib in Relapsed or Refractory ... StreetInsider.com
Investing News Network  -Healio  -AML Global Portal 
all 6 news articles »